ISSAR Pharma, the only company in India which focuses on research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population, and making it affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice, and has the capability to synthesize custom peptides, API peptides and cosmetic peptides at all scales within a short duration.
With emphasis on quality, safety and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology and diseases of bones and joints.

“We take pride in being India’s first ever company to conduct phase-1 clinical trials, and launch the first ever indigenous peptide drug, Melgain in market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, Founder and Chairman of ISSAR Pharmaceuticals.

ISSAR’s FDA – compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing highest standards of purity of up to 99.5% by continued process optimization.





Source link

Author

Write A Comment

//thaudray.com/4/3584464